Clinical trials: Prostate Cancer Recurrent
Hot Flashes, Prostate Cancer
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
RATIONALE: Soy protein/isoflavones and venlafaxine may help relieve hot flashes in patients receiving hormone therapy for prostate cancer.
- Trial name
- NCT00354432
- Testing
- oral soy protein/isoflavones powder, Venlafaxine
- Where
- 20 sites in United States
- Volunteers
- 120 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery
Patients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive disease features will receive salvage radiation therapy and standard androgen deprivation therapy (ADT) or enhanced ADT to determine if…
- Trial name
- STEEL (NCT03809000)
- Testing
- Radiation Therapy, Enzalutamide, Bicalutamide
- Where
- 108 sites in United States, Canada
- Volunteers
- 188 people
- Sponsor
- RTOG Foundation, Inc.
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This phase II trial studies how well orteronel works in treating patients with metastatic hormone-resistant prostate cancer. Orteronel may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01866423
- Testing
- orteronel, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Southern California
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
This phase II trial studies genetic and molecular mechanisms in assessing response in patients with prostate cancer receiving enzalutamide therapy. Androgens can cause the growth of prostate cancer cells.
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Prostate Adenocarcinoma
- Trial name
- NCT02099864
- Testing
- Enzalutamide
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Rationale: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known if vaccine therapy is effective for prostate cancer.
- Trial name
- NCT00005947
- Testing
- sipuleucel-T
- Where
- 34 sites in United States
- Volunteers
- 127 people
- Sponsor
- Dendreon
Biochemically Recurrent Prostate Cancer
A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide
Researchers are looking for a better way to treat men who have biochemically recurrent hormone-naïve prostate cancer. Hormone-naïve prostate cancer is a prostate cancer that has not yet been treated with hormonal therapy…
- Trial name
- ARAMON (NCT05526248)
- Testing
- Darolutamide(BAY1841788, Nubeqa), Enzalutamide
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Bayer
Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant
Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
This study investigates if a new drug (PSMA) makes prostate cancer easier to identify in positron-emission tomography (PET) imaging.
- Trial name
- NCT03822845
- Testing
- Ga-68 PSMA-HBED-CC PET
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Michael Graham PhD, MD
Prostate Cancer, Prostatic Neoplasm
Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
Background: Prostate cancer is the second leading cause of cancer death in United States (U.S.) men. Radiation is an effective treatment for most patients with localized prostate cancer, but sometimes the tumor returns.
- Trial name
- NCT03253744
- Testing
- 18F-DCFPyL, Tumor Irradiation, Prostate + tumor irradiation
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Cancer, Prostate Cancer
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
RATIONALE: Zoledronate may prevent or decrease skeletal (bone)-related events (such as pain or fractures) caused by bone metastases and androgen deprivation therapy.
- Trial name
- NCT00079001
- Testing
- zoledronic acid, androgen deprivation therapy, GnRH agonist
- Where
- 241 sites in United States, Canada
- Volunteers
- 645 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer
- Trial name
- MDX1106-01 (NCT00441337)
- Testing
- MDX-1106
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as ketoconazole, may stop the adrenal glands from making androgens.
- Trial name
- NCT00460031
- Testing
- ketoconazole, lenalidomide, therapeutic hydrocortisone
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
FACBC PET/CT for Recurrent Prostate Cancer
Hypothesis:Anti-[18F]FACBC PET-CT will adequately detect local and extraprostatic recurrence, and lead to better characterization of disease status in restaging patients.
- Trial name
- NCT00562315
- Testing
- FACBC, ProstaScinct
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- David M. Schuster, MD
Prostate Cancer
Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer
The purpose of this study is to assess the effect of combining abiraterone with medicines that may block some of the ways that cells become resistant to abiraterone.
- Trial name
- NCT01828476
- Testing
- Abiraterone, ABT-263, Hydroxychloroquine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Rutgers, The State University of New Jersey
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This phase II trial studies how well ipilimumab works when given together with androgen suppression therapy in treating patients with hormone-resistant prostate cancer that has spread to other parts of the body.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01498978
- Testing
- ipilimumab, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- OHSU Knight Cancer Institute
Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body…
- Conditions
- Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma
- Trial name
- NCT04514484
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Green Tea, Black Tea, or Water in Treating Patients With Prostate Cancer Undergoing Surgery
RATIONALE: Green tea contains ingredients that may prevent or slow the growth of certain cancers. It is not yet known whether green tea is more effective than black tea or water in treating prostate cancer.
- Trial name
- NCT00685516
- Testing
- green tea, decaffeinated black tea
- Where
- 2 sites in United States
- Volunteers
- 113 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
PROvenge Treatment and Early Cancer Treatment
The PROTECT-PROvenge Treatment and Early Cancer Treatment trial was a Phase III trial for patients with hormone sensitive prostate cancer. The study was conducted at over 15 participating centers throughout the US.
- Trial name
- PROTECT (NCT00779402)
- Testing
- Control, Sipuleucel-T
- Where
- 18 sites in United States
- Volunteers
- 176 people
- Sponsor
- Dendreon
Prostate Cancer
18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer
This is an interventional, single group assignment, prospective nonrandomized, open label Phase 2 trial designed to evaluate 18F-DCFPyL PET imaging in men diagnosed with prostate cancer with increasing prostate-specific antigen…
- Trial name
- NCT04727736
- Testing
- 18F-DCFPyL
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Ashok Muthukrishnan
Hormone-refractory Prostate Cancer, Adenocarcinoma of the Prostate
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer
The purpose of this research study is to find out if a new anti-cancer drug, dasatinib (Sprycel®), previously approved for treatment of some forms of leukemia, will be safe and helpful in treating patients with hormone-refractory…
- Conditions
- Hormone-refractory Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Prostate Cancer
- Trial name
- NCT00570700
- Testing
- Dasatinib
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- University of California, Irvine
Metastatic Prostate Cancer
Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
This Phase 3 study will target approximately 100 men over age 18 who have a biochemical relapse or other evidence of relapse of prostate cancer after primary treatment. The purpose of this study is to: A.
- Trial name
- NCT02260817
- Testing
- 11C-choline Injection
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Global Isotopes, LLC d/b/a Zevacor Molecular